Inventor · disambiguated record
Michal Geva
Also filed as: GEVA MICHAL
9 granted patents·23 pending applications·14 citations·filing 2009–2025
81Inventor score
Files withPrilenia Neurotherapeutics Ltd29APICA CARDIOVASCULAR IRELAND LTD1PRILENIA THERAPEUTICS DEV LTD1TEICHMAN EYAL1
Top patents by PatentIndex Score
32 records- 0184US11406625B2Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2020·Granted Aug 9, 2022·2 cites·15 claims
- 0284US10603311B2Use of pridopidine to improve cognitive function and for treating Alzheimer's diseasePrilenia Neurotherapeutics Ltd·Filed 2016·Granted Mar 31, 2020·4 cites·12 claims
- 0383US12102627B2Use of pridopidine for treating rett syndromePrilenia Neurotherapeutics Ltd·Filed 2020·Granted Oct 1, 2024·1 cites·25 claims
- 0478US2025360121A1Pridopidine for treating huntington's diseasePrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 0574US11738012B2Treatment of neurodegenerative eye disease using pridopidinePrilenia Neurotherapeutics Ltd·Filed 2017·Granted Aug 29, 2023·1 cites·42 claims
- 0671US2024398778A1Use of pridopidine for treating rett syndromePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 0767US11000519B2Pridopidine for treating drug induced dyskinesiasPrilenia Neurotherapeutics Ltd·Filed 2019·Granted May 11, 2021·0 cites·20 claims
- 0866US2025082619A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 0966US2023181548A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 1064US9265497B2Tissue access site system and methodTEICHMAN EYAL·Filed 2009·Granted Feb 23, 2016·6 cites·25 claims
- 1164US2024148708A1Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 1262US2023330073A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 1362US2024261273A1Pridopidine and analogs thereof for the treatment of neurodegenerative eye diseasePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 1462US2023355595A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 1560US12036213B2Pridopidine for treating drug induced dyskinesiasPrilenia Neurotherapeutics Ltd·Filed 2021·Granted Jul 16, 2024·0 cites·29 claims
- 1660US2021220342A1Pridopidine for the treatment of mitochondrial-associated diseases and disorders and endoplasmic reticulum (er) stressPrilenia Neurotherapeutics Ltd·Filed 2021·Application pending·0 cites
- 1759US2025221972A1Pridopidine for the treatment of mitochondrial-associated diseases and disordersPrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 1859US2023190724A1Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 1958US2023100072A1Treatment of viral infection, disease or disorder using a selective s1r agonistPrilenia Neurotherapeutics Ltd·Filed 2022·Application pending·0 cites
- 2058US2025352533A1Pridopidine for treating huntington's diseasePrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 2158US2023112948A1Use of pridopidine for treating anxiety and depressionPrilenia Neurotherapeutics Ltd·Filed 2022·Application pending·0 cites
- 2258US2021052560A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2020·Application pending·0 cites
- 2356US2023414596A1Use of pridopidine and analogs for treating rett syndromePrilenia Neurotherapeutics Ltd·Filed 2021·Application pending·0 cites
- 2456US2024197708A1Treatment of prodromal huntington diseasePrilenia Neurotherapeutics Ltd·Filed 2022·Application pending·0 cites
- 2555US2023390272A1Use of pridopidine and analogs for the treatment of anxiety and depressionPrilenia Neurotherapeutics Ltd·Filed 2021·Application pending·0 cites
- 2655US2025319076A1Use of pridopidine and analogs for treating symptoms of huntington diseasePrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 2753US2022062255A1Treatment of neurodegenerative eye disease using pridopidinePrilenia Neurotherapeutics Ltd·Filed 2021·Application pending·0 cites
- 2852US11471449B2Use of pridopidine to improve cognitive function and for treating Alzheimer's diseasePrilenia Neurotherapeutics Ltd·Filed 2019·Granted Oct 18, 2022·0 cites·17 claims
- 2951US2021030734A1Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2020·Application pending·0 cites
- 3048US12357624B2Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonismPrilenia Neurotherapeutics Ltd·Filed 2020·Granted Jul 15, 2025·0 cites·21 claims
- 3148US2016135833A1Tissue access site system and methodAPICA CARDIOVASCULAR IRELAND LTD·Filed 2016·Application pending·0 cites
- 3245US2019231768A1Pridopidine for treating drug induced dyskinesiasPRILENIA THERAPEUTICS DEV LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michal Geva files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →